Stockreport
What's in the Cards for Amgen (AMGN) This Earnings Season? [Yahoo! Finance]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
Factors to Consider Amgen's product sales are expected to be the lowest in the first quarter per historical trends due to the impact of benefit plan changes, insurance re-verification and increased co-pay expenses as U.S. patients work through deductibles. First-quarter 2024 total revenues are expected to grow roughly 20% year over year. The Zacks Consensus Estimate for total revenues is $7.38 billion. Amgen's product sales are expected to have been driven by strong volume growth of products like Evenity, Repatha, Prolia, and Blincyto, among others. However, prices of most products are expected to have declined. The Zacks Consensus Estimate for Prolia, Repatha, Evenity and Blincyto sales are pegged at $1.0 billion, $452.3 million, $334.0 million and $240.0 million, respectively. Our estimates for Prolia, Repatha, Evenity and Blincyto sales are pegged at $997 million, $448.0 million, $330.8 million and $227.1 million, respectively. In addition, higher volumes of newer drugs
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024[PR Newswire]
- Bone Metastasis Treatment Market To Reach USD 38.5 Billion By 2032 | DataHorizzon Research [Yahoo! Finance][Yahoo! Finance]
- We Wouldn't Be Too Quick To Buy Amgen Inc. (NASDAQ:AMGN) Before It Goes Ex-Dividend [Yahoo! Finance][Yahoo! Finance]
- Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates [Yahoo! Finance][Yahoo! Finance]
- AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE[PR Newswire]
- More
AMGN
SEC Filings
SEC Filings
- 5/10/24 - Form DEFA14A
- 5/9/24 - Form 4
- 5/9/24 - Form 4
- AMGN's page on the SEC website
- More